Biotech company Imperagen announced on Thursday a £5 million ($6.7 million) seed round led by PXN Ventures, with participation from IQ Capital and Northern Gritstone. The company was founded in 2021 by Manchester Institute of Biotechnology scientists Dr. Andrew Currin, Dr. Tim Eyes, and Dr. Andy Almond and spun out of the university.
The startup seeks to improve enzyme engineering by making it faster, more efficient, and less costly than the slower, more physical, trial-and-error-focused process used now.
Imperagen is using three core technologies as it seeks to redefine enzyme engineering. Specifically, it uses a quantum physics-based simulation instead of trial-and-error enzyme mutations in a lab. Imperagen predicts the behavior of enzyme variants on a computer using advanced quantum physics modeling that can explore millions of mutations, the company said. Then it translates this information into its custom AI models, trained on the enzyme problems Imperagen seeks to explore. Finally, to retain its AI models, Imperagen uses robots and automation to generate experimental data, which is fed back to the AI model, in a process called closed-loop simulation.
Enzymes are incredibly important across many industries, especially in pharmaceuticals, as they are essential to drug development. Startups like Imperagen are hoping to speed up enzyme engineering because it can have a domino effect, making, for example, drug discovery faster and more efficient. Enzymes are also used in sectors like food, biofuels, and agriculture. Experts in sustainability are also looking to enzymes — and the AI technologies surrounding them — to make industrial production and manufacturing more sustainable.
Others in this space include Biomatter, Cradle Bio, and Absci.
On Thursday, Imperagen also announced that Guy Levy-Yurista will assume the role of CEO. Speaking to TechCrunch, he said that right now, the process of enzyme engineering is falling short, where even many new AI-powered technologies can pass trial and error but fail when put into practice on an industrial scale.
Imperagen hopes its tech will make enzyme development “faster, more reliable, and more commercially accessible, helping companies bring better bio-based products to market without the long timelines and uncertainty that have traditionally held the field back,” he told TechCrunch.
Levy-Yurista has a background in AI, life sciences, and enterprise technology. Though the founders will remain at the company, Levy-Yurista was brought in to help build out its new technologies, including a vertical AI infrastructure for biocatalysis (a process that accelerates chemical reactions using natural catalysts like enzymes), while scaling the startup’s AI strategy, commercial models, and industrial partnerships.
The company has raised £8.5 million ($11.42 million) in funding to date and the fresh capital will be used to hire more AI specialists, put toward research and development, expand its experimental lab capabilities, and build a go-to-market function within the next two years.
“Ultimately, Imperagen hopes wider use of engineered enzymes will help industries reliably produce products that are cleaner, safer and better for people and the planet, while also making commercial sense for the companies that adopt them,” Levy-Yurista said.
When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.
No Comment! Be the first one.